Open house drug discount agreements Ranibizumab injection solution vial
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Durchstechflasche, ATC S01LA04
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No value or volume estimates available; may attract many participants, diluting potential benefit.
Open-house agreements automatically terminate if a standard competitive discount agreement for the same substance is si...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Supply of Ranibizumab (ATC S01LA04) in injection solution form in vial
- Participation in a non-exclusive drug discount scheme with AOK Bayern
Show full summary
This is an open-house model for non-exclusive drug discount agreements (Rabattverträge) for the active substance Ranibizumab (injection solution, vial, ATC S01LA04) with AOK Bayern. It is not a traditional procurement procedure; any eligible pharmaceutical company can join under identical, non-negotiable terms. The contract period is from 1 May 2025 to 30 April 2027, with possible early termination. No estimated value is published. Only one lot is identified.
Risks
No value or volume estimates available; may attract many participants, diluting potential benefit.
Open-house agreements automatically terminate if a standard competitive discount agreement for the same substance is si...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible to participate
Administrative
- Must submit a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Contract, annex specifying covered medicines, and self-declaration must be submitted in paper (2 copies) or electronically with qualified electronic signature
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house drug discount agreements Ranibizumab injection solution vial
Non-exclusive discount agreements for Ranibizumab injection solution in vial form. All interested pharmaceutical companies meeting eligibility can sign identical contracts.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Durchstechflasche, ATC S01LA04
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 18 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 176237-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No value or volume estimates available; may attract many participants, diluting potential benefit.
Open-house agreements automatically terminate if a standard competitive discount agreement for the same substance is si...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications